Vistagen Therapeutics, Inc. (VTGN)
0.2434
+0.01
(+3.35%)
USD |
NASDAQ |
Sep 10, 16:00
0.2434
0.00 (0.00%)
After-Hours: 16:38
Vistagen Therapeutics Enterprise Value : -20.50M for Sept. 9, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 09, 2026 | -20.50M |
| September 08, 2026 | -20.14M |
| September 04, 2026 | -20.17M |
| September 03, 2026 | -20.02M |
| September 02, 2026 | -20.03M |
| September 01, 2026 | -20.15M |
| August 31, 2026 | -19.63M |
| August 28, 2026 | -19.72M |
| August 27, 2026 | -19.54M |
| August 26, 2026 | -19.41M |
| August 25, 2026 | -19.92M |
| August 24, 2026 | -20.13M |
| August 21, 2026 | -20.12M |
| August 20, 2026 | -20.25M |
| August 19, 2026 | -20.11M |
| August 18, 2026 | -20.21M |
| August 17, 2026 | -19.41M |
| August 14, 2026 | -19.07M |
| August 13, 2026 | -19.13M |
| August 12, 2026 | -19.35M |
| August 11, 2026 | -19.00M |
| August 10, 2026 | -19.24M |
| August 07, 2026 | -18.18M |
| August 06, 2026 | -18.35M |
| August 05, 2026 | -17.77M |
| Date | Value |
|---|---|
| August 04, 2026 | -17.63M |
| August 03, 2026 | -20.07M |
| July 31, 2026 | -20.25M |
| July 30, 2026 | -20.25M |
| July 29, 2026 | -20.15M |
| July 28, 2026 | -20.62M |
| July 27, 2026 | -20.73M |
| July 24, 2026 | -20.90M |
| July 23, 2026 | -20.92M |
| July 22, 2026 | -20.57M |
| July 21, 2026 | -20.52M |
| July 20, 2026 | -20.69M |
| July 17, 2026 | -20.77M |
| July 16, 2026 | -20.30M |
| July 15, 2026 | -19.90M |
| July 14, 2026 | -20.02M |
| July 13, 2026 | -19.73M |
| July 10, 2026 | -19.50M |
| July 09, 2026 | -19.89M |
| July 08, 2026 | -20.53M |
| July 07, 2026 | -20.43M |
| July 06, 2026 | -20.04M |
| July 02, 2026 | -19.90M |
| July 01, 2026 | -20.16M |
| June 30, 2026 | -20.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.882B |
| Alnylam Pharmaceuticals, Inc. | 34.18B |
| Anika Therapeutics, Inc. | 266.28M |
| Savara, Inc. | 969.61M |
| Vericel Corp. | 1.927B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -13.03M |
| Revenue (Quarterly) | 1.476M |
| Total Expenses (Quarterly) | 14.51M |
| EPS Diluted (Quarterly) | -0.3032 |
| Gross Profit Margin (Quarterly) | 86.65% |
| Profit Margin (Quarterly) | -882.8% |
| Earnings Yield | -700.4% |
| Normalized Earnings Yield | -700.29 |